X
Search Filters
Format Format
Subjects Subjects
Subjects Subjects
X
Sort by Item Count (A-Z)
Filter by Count
humans (66) 66
female (57) 57
male (56) 56
adult (50) 50
middle aged (44) 44
aged (41) 41
antineoplastic combined chemotherapy protocols - therapeutic use (26) 26
oncology (26) 26
adolescent (25) 25
aged, 80 and over (19) 19
index medicus (17) 17
lymphoma, non-hodgkin - drug therapy (17) 17
cancer (16) 16
chemotherapy (14) 14
gallium radioisotopes (14) 14
prognosis (13) 13
animals (12) 12
doxorubicin - administration & dosage (12) 12
lymphoma (12) 12
lymphoma, non-hodgkin - mortality (12) 12
lymphomas (12) 12
treatment outcome (11) 11
vincristine - administration & dosage (11) 11
cyclophosphamide - administration & dosage (10) 10
hodgkin disease - drug therapy (10) 10
prednisone - administration & dosage (10) 10
retrospective studies (10) 10
child (9) 9
hodgkin disease - diagnostic imaging (9) 9
neoplasm staging (9) 9
therapy (9) 9
antineoplastic combined chemotherapy protocols - adverse effects (8) 8
hodgkin disease - mortality (8) 8
patients (8) 8
prospective studies (8) 8
survival analysis (8) 8
tomography, emission-computed, single-photon (8) 8
tomography, x-ray computed (8) 8
drug administration schedule (7) 7
etoposide - administration & dosage (7) 7
lymphoma, non-hodgkin - diagnostic imaging (7) 7
neurosciences (7) 7
non-hodgkin's lymphomas (7) 7
pancreatic cancer (7) 7
survival rate (7) 7
disease (6) 6
disease-free survival (6) 6
follow-up studies (6) 6
hodgkin disease (6) 6
lymphoma - diagnostic imaging (6) 6
lymphoma, non-hodgkin - therapy (6) 6
radionuclide imaging (6) 6
sensitivity and specificity (6) 6
tomography (6) 6
alzheimer's disease (5) 5
antineoplastic combined chemotherapy protocols - administration & dosage (5) 5
biomarkers (5) 5
combination chemotherapy (5) 5
combined modality therapy (5) 5
disease progression (5) 5
fdg-pet (5) 5
gallium, radioactive (5) 5
hematology (5) 5
lymphoma, radionuclide studies (5) 5
positron-emission tomography (5) 5
positron-emission-tomography (5) 5
predictive value of tests (5) 5
radiology and nuclear medicine (5) 5
radiology, nuclear medicine & medical imaging (5) 5
radiotherapy (5) 5
remission induction (5) 5
somatostatin (5) 5
survival (5) 5
vincristine - adverse effects (5) 5
adenocarcinoma - drug therapy (4) 4
case-control studies (4) 4
child, preschool (4) 4
consensus (4) 4
dementia (4) 4
diagnosis (4) 4
endocrinology & metabolism (4) 4
etoposide - adverse effects (4) 4
genetics (4) 4
hodgkin disease - therapy (4) 4
lymphoma - drug therapy (4) 4
lymphoma - mortality (4) 4
lymphoma, large b-cell, diffuse - mortality (4) 4
malignant-lymphoma (4) 4
mice (4) 4
multivariate analysis (4) 4
non-hodgkin's lymphoma (4) 4
non-hodgkins-lymphoma (4) 4
pancreatic neoplasms - drug therapy (4) 4
pancreatic neoplasms - pathology (4) 4
pet/ct (4) 4
prednisone - adverse effects (4) 4
prognostic factors (4) 4
radioisotope scanning (4) 4
research (4) 4
risk (4) 4
more...
Library Location Library Location
Language Language
Publication Date Publication Date
Click on a bar to filter by decade
Slide to change publication date range


Nature Genetics, ISSN 1061-4036, 09/2017, Volume 49, Issue 9, pp. 1373 - 1384
Journal Article
Journal Article
Journal Article
British Journal of Cancer, ISSN 0007-0920, 03/2017, Volume 116, Issue 6, pp. 694 - 702
Journal Article
by Kunkle, BW and Grenier-Boley, B and Sims, R and Bis, JC and Damotte, V and Naj, AC and Boland, A and Vronskaya, M and van der Lee, SJ and Amlie-Wolf, A and Bellenguez, C and Frizatti, A and Chouraki, V and Martin, ER and Sleegers, K and Badarinarayan, N and Jakobsdottir, J and Hamilton-Nelson, KL and Moreno-Grau, S and Olaso, R and Raybould, R and Chen, YN and Kuzma, AB and Hiltunen, M and Morgan, T and Ahmad, S and Vardarajan, BN and Epelbaum, J and Hoffmann, P and Boada, M and Beecham, GW and Garnier, JG and Harold, D and Fitzpatrick, AL and Valladares, O and Moutet, ML and Gerrish, A and Smith, AV and Qu, LM and Bacq, D and Denning, N and Jian, XQ and Zhao, Y and Del Zompo, M and Fox, NC and Choi, SH and Mateo, I and Hughes, JT and Adams, HH and Malamon, J and Sanchez-Garcia, F and Patel, Y and Brody, JA and Dombroski, BA and Naranjo, MCD and Daniilidou, M and Eiriksdottir, G and Mukherjee, S and Wallon, D and Uphill, J and Aspelund, T and Cantwell, LB and Garzia, F and Galimberti, D and Hofer, E and Butkiewicz, M and Fin, B and Scarpini, E and Sarnowski, C and Bush, WS and Meslage, S and Kornhuber, J and White, CC and Song, Y and Barber, RC and Engelborghs, S and Sordon, S and Voijnovic, D and Adams, PM and Vandenberghe, R and Mayhaus, M and Cupples, LA and Albert, MS and De Deyn, PP and Gu, W and Himali, JJ and Beekly, D and Squassina, A and Hartmann, AM and Orellana, A and Blacker, D and Rodriguez-Rodriguez, E and Lovestone, S and Garcia, ME and Doody, RS and Munoz-Fernadez, C and Sussams, R and Lin, HH and Fairchild, TJ and Benito, YA and ... and Cohorts Heart Aging Res Genomic Ep and Alzheimer Dis Genetics Consortium and European Alzheimers Dis Initiative and Genetic Environm Risk AD Defining and Alzheimer Disease Genetics Consortium (ADGC) and Cohorts for Heart and Aging Research in Genomic Epidemiology Consortium (CHARGE) and European Alzheimer’s Disease Initiative (EADI) and Genetic and Environmental Risk in AD/Defining Genetic, Polygenic and Environmental Risk for Alzheimer’s Disease Consortium (GERAD/PERADES) and Stockholms universitet and Centrum för forskning om äldre och åldrande (ARC), (tills m KI) and Samhällsvetenskapliga fakulteten
NATURE GENETICS, ISSN 1061-4036, 03/2019, Volume 51, Issue 3, pp. 414 - 414
Risk for late-onset Alzheimer's disease (LOAD), the most prevalent dementia, is partially driven by genetics. To identify LOAD risk loci, we performed a large... 
COMMON VARIANTS | GENOTYPE IMPUTATION | AMYLOID-BETA | GENETICS & HEREDITY | DOMAIN-CONTAINING OXIDOREDUCTASE | MUTATIONS | ANGIOTENSIN-CONVERTING ENZYME | TRANSCRIPTION FACTOR | ONSET | GENOME-WIDE ASSOCIATION | APOLIPOPROTEIN-E | Genetic Predisposition to Disease - genetics | Lipids - genetics | Humans | Genetic Loci - genetics | Male | Genetic Testing - methods | Case-Control Studies | Haplotypes - genetics | tau Proteins - genetics | Amyloid beta-Peptides - genetics | Female | Lipid Metabolism - genetics | Aged | Alzheimer Disease - genetics | Genome-Wide Association Study - methods | Immunity - genetics | Ontology | Genomics | Genes | Lipids | Genomes | Mapping | Family medical history | Immunity | Risk factors | Protein turnover | Datasets | Proteins | Consortia | Genetic analysis | Dementia disorders | Genetics | Lipid metabolism | Alzheimer's disease | Age | ADAMTS-1 protein | Neurodegenerative diseases | Health risks | Metabolism | Risk analysis | Amyloid precursor protein | Meta-analysis | White blood cells | Genetic variance | Tau protein | Histocompatibility antigen HLA | Gene loci | Gene mapping | Alzheimers disease | Secretase | Dementia | Index Medicus | Basic Medicine | Medical Genetics | Medicinsk genetik | Medical and Health Sciences | Medicin och hälsovetenskap | Medicinska och farmaceutiska grundvetenskaper
Journal Article
Journal of Nuclear Medicine, ISSN 0161-5505, 02/2014, Volume 55, Issue 2, pp. 351 - 352
Journal Article
The Journal of Nuclear Medicine, ISSN 0161-5505, 01/2010, Volume 51, Issue 1, pp. 25 - 30
Journal Article
British Journal of Haematology, ISSN 0007-1048, 09/2017, Volume 178, Issue 5, pp. 709 - 718
Summary This multicentre study evaluated 5‐year progression‐free (PFS) and overall survival (OS) in early and advanced Hodgkin lymphoma (HL), where therapy was... 
advanced‐stage Hodgkin lymphoma | interim positron emission tomography/computed tomography | early‐stage Hodgkin lymphoma | radiation therapy | Hodgkin lymphoma | early-stage Hodgkin lymphoma | advanced-stage Hodgkin lymphoma | RISK | INTERNATIONAL PROGNOSTIC SCORE | CHEMOTHERAPY | RADIATION-THERAPY | ABVD | POSITRON-EMISSION-TOMOGRAPHY | ESCALATED BEACOPP | RESPONSE-ADAPTED THERAPY | INTERPRETATION CRITERIA | HEMATOLOGY | COOPERATIVE-ONCOLOGY-GROUP | Hodgkin Disease - diagnostic imaging | Procarbazine - administration & dosage | Cyclophosphamide - administration & dosage | Dacarbazine - adverse effects | Antineoplastic Combined Chemotherapy Protocols - administration & dosage | Prognosis | Prospective Studies | Hodgkin Disease - pathology | Humans | Middle Aged | Antineoplastic Combined Chemotherapy Protocols - adverse effects | Male | Drug Monitoring - methods | Vinblastine - administration & dosage | Cyclophosphamide - adverse effects | Young Adult | Vinblastine - adverse effects | Vincristine - administration & dosage | Adult | Female | Radiotherapy, Adjuvant | Doxorubicin - administration & dosage | Dacarbazine - administration & dosage | Prednisone - administration & dosage | Etoposide - adverse effects | Prednisone - adverse effects | Drug Administration Schedule | Kaplan-Meier Estimate | Etoposide - administration & dosage | Bleomycin - administration & dosage | Bleomycin - adverse effects | Positron Emission Tomography Computed Tomography | Procarbazine - adverse effects | Antineoplastic Combined Chemotherapy Protocols - therapeutic use | Hodgkin Disease - therapy | Adolescent | Vincristine - adverse effects | Neoplasm Staging | Doxorubicin - adverse effects | CT imaging | Anthracyclines | Corticosteroids | PET imaging | Analysis | Lymphomas | Radiotherapy | Procarbazine | Vinblastine | Positron emission | Etoposide | Prednisone | Radiation therapy | Lymphoma | Patients | Vincristine | Dacarbazine | Cyclophosphamide | Bleomycin | Computed tomography | Medical prognosis | Tomography | Positron emission tomography | Hodgkin's disease
Journal Article
Journal of Nuclear Medicine, ISSN 0161-5505, 01/2013, Volume 54, Issue 1, pp. 12 - 18
Journal Article
International Journal of Radiation Oncology, Biology, Physics, ISSN 0360-3016, 2012, Volume 82, Issue 1, pp. 315 - 320
Purpose Involvement of salivary glands with mucosa-associated lymphoid tissue (MALT) lymphoma is rare. This retrospective study was performed to assess the... 
Radiology | Hematology, Oncology and Palliative Medicine | Mucosa-associated lymphoid tissue lymphoma | Chemotherapy | Salivary glands | Radiotherapy | HEAD | SINGLE-CENTER EXPERIENCE | PAROTID-GLAND | NON-HODGKINS-LYMPHOMAS | MALT LYMPHOMAS | FEATURES | B-CELL LYMPHOMA | THERAPY | ONCOLOGY | DISEASE | NECK | RADIOLOGY, NUCLEAR MEDICINE & MEDICAL IMAGING | Salivary Gland Neoplasms - mortality | Humans | Middle Aged | Lymphoma, B-Cell, Marginal Zone - therapy | Male | Salivary Glands, Minor | Lymphoma, B-Cell, Marginal Zone - mortality | Aged, 80 and over | Parotid Neoplasms - therapy | Adult | Female | Lymphoma, B-Cell, Marginal Zone - pathology | Rare Diseases - pathology | Retrospective Studies | Submandibular Gland Neoplasms - therapy | Submandibular Gland Neoplasms - pathology | Rare Diseases - mortality | Submandibular Gland Neoplasms - mortality | Disease Progression | Disease-Free Survival | Rare Diseases - therapy | Parotid Neoplasms - mortality | Antineoplastic Combined Chemotherapy Protocols - therapeutic use | Salivary Gland Neoplasms - therapy | Parotid Neoplasms - pathology | Aged | Combined Modality Therapy - methods | Neoplasm Staging | Salivary Gland Neoplasms - pathology | Medical colleges | Research | Non-Hodgkin's lymphomas | Nuclear radiation | Oncology, Experimental | Cancer | LYMPHOMAS | SURGERY | PATIENTS | LYMPH NODES | SALIVARY GLANDS | RADIOLOGY AND NUCLEAR MEDICINE | FEMALES | RADIOTHERAPY | MALES | CHEMOTHERAPY | MUCOUS MEMBRANES
Journal Article
15.